Prostate News Archive
04-Jun-2008
Brisbane scientists target cause of prostate cancer (ABC via Yahoo!7 News)
Brisbane scientists say they are conducting a world-first study to pinpoint the cause of prostate cancer. Medivation Announces Presentation Of Positive MDV3100 Clinical Data In Castration-Resistant Prostate Cancer Patients ... (Medical News Today)
Medivation, Inc. (Nasdaq: MDVN) announced that data from an ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist, MDV3100, showed encouraging anti-tumor activity as measured by declining serum levels of prostate specific antigen (PSA) and circulating tumor cells (CTC), as well as radiographic disease stabilization, after three months of treatment. Drug Found To Stimulate Immune System In Patients With Prostate Cancer (Science Daily)
Researchers have found that a drug called Ipilimumab, also known as MDX-010, works to stimulate the body's own immune system to fight prostate cancer. The drug was found to be effective in study participants with a serious type of prostate cancer -- one where the tumor has spread and was resistant to hormonal treatment and, in some cases, also to chemotherapy. Bavarian Nordic enters trials with prostate cancer vaccine (News-Medical-Net)
Bavarian Nordic's subsidiary, BN ImmunoTherapeutics has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer. Interim Phase 1/2 Data Of Ipilimumab In Prostate Cancer Presented At American Society Of Clinical Oncology Annual ... (Medical News Today)
Medarex, Inc. (Nasdaq: MEDX) announced interim results from a Phase 1/2 trial of ipilimumab, an investigational oncology immunotherapy, as monotherapy or in combination with radiotherapy in patients with metastatic castration resistant prostate cancer (mCRPC).
Back to Prostate News Archive
